Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2014; 20(43): 16275-16281
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16275
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16275
Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture
Shun-Zhen Zheng, Guang-Sheng Yu, Yan-Tian Xu, Wei Gong, Jun Liu, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China
De-Jie Liu, Department of Anesthesiology, Qilu Hospital, Shandong University, Jinan 250012, Shandong Province, China
Ping Sun, Department of Biochemistry and Molecular Biology, Shandong University School of Medicine, Jinan 250012, Shandong Province, China
Author contributions: Liu J and Zheng SZ designed the research; Zheng SZ, Liu DJ, Sun P and Yu GS performed the research; Xu YT and Gong W analyzed the data; Zheng SZ wrotes the manuscript.
Supported by National Natural Science Foundation of China, No. 81302124
Correspondence to: Jun Liu, Professor, Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan 250021, Shandong Province, China. dr_liujun@hotmail.com
Telephone: +86-531-68776932 Fax: +86-531-87925615
Received: June 16, 2014
Revised: July 21, 2014
Accepted: August 13, 2014
Published online: November 21, 2014
Processing time: 157 Days and 12.6 Hours
Revised: July 21, 2014
Accepted: August 13, 2014
Published online: November 21, 2014
Processing time: 157 Days and 12.6 Hours
Core Tip
Core tip: Spontaneous rupture of hepatocellular carcinoma (HCC) is a life-threatening condition. Currently, sorafenib is available for HCC patients with spontaneous rupture, although its efficacy and safety have not been reported. This study aims to report the outcome of patients with ruptured HCC in a single center during a 5-year period. We retrospectively analyzed 32 patients who presented with ruptured HCC at our institute between 2008 and 2013. We concluded that sorafenib can be used in patients with ruptured HCC as it has interesting activity and is well tolerated. However, a larger prospective study is necessary to determine the efficacy of sorafenib in this group of patients.